About Us


BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.


Found 24 results
Filters: Author is Logan, Brent  [Clear All Filters]
C. G. Brunstein, O'Donnell, P. V., Logan, B., Dawson, P., Costa, L., Cutler, C., Craig, M., Hogan, W., Horowitz, M. M., Horwitz, M. E., Karanes, C., Magenau, J. M., Malone, A., McCarty, J., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Salit, R., Vasu, S., Eapen, M., and Fuchs, E. J., Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012., Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
N. Farhadfar, Ahn, K. Woo, Bo-Subait, S., Logan, B., Stefanski, H. E., Hsu, J. W., Panch, S., Confer, D., Liu, H., Badawy, S. M., Beitinjaneh, A., Diaz, M. A., Hildebrandt, G. C., Kelkar, A. H., Lazarus, H. M., Murthy, H. S., Preussler, J. M., Schears, R. M., Sharma, A., van der Poel, M., Bruce, J. G., Pulsipher, M. A., Shaw, B. E., Wingard, J. R., and Switzer, G. E., The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials., Transplant Cell Ther, 2022.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies., J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.